JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Accueil・Liste d'Actions・Aclaris Therapeutics Inc

Search

Aclaris Therapeutics Inc

Fermé

4.41 1.85

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.33

Max

4.41

Chiffres clés
By Trading Economics
Revenu	-5.2M -20M
Ventes	-2M 1.3M
Marge bénéficiaire	-1,528.571
Employés	69
EBITDA	-5.3M -20M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+156.92% upside

Dividendes
By Dow Jones
Prochains Résultats	7 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	264M 616M
Ouverture précédente	2.56
Clôture précédente	4.41

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

1.28 / 1.33 Support & Résistance

Aclaris Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mai 2026, 22:17 UTC

Résultats

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mai 2026, 23:47 UTC

Résultats

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mai 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Shareholders to Own About 51% of Combined Company

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Board Unanimously Endorsed, Supported Deal

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Deal Unanimously Recommended by Vault Board

4 mai 2026, 22:39 UTC

Acquisitions, Fusions, Rachats

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources to Acquire All Ordinary Shares in Vault

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mai 2026, 22:37 UTC

Résultats

Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mai 2026, 22:26 UTC

Résultats

Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mai 2026, 22:02 UTC

Résultats

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mai 2026, 21:52 UTC

Résultats

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mai 2026, 21:50 UTC

Résultats

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mai 2026, 21:50 UTC

Résultats

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mai 2026, 21:49 UTC

Résultats

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mai 2026, 21:43 UTC

Résultats

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mai 2026, 21:41 UTC

Résultats

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mai 2026, 21:40 UTC

Résultats

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparaison

Variation de prix

Aclaris Therapeutics Inc prévision

Objectif de Prix

By TipRanks

156.92% hausse

Prévisions sur 12 Mois

Moyen 11.33 USD 156.92%

Haut 16 USD

Bas 10 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.28 / 1.33Support & Résistance

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Autres valeurs du secteur

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat